All In Biotech

Drug Trial Radar · NCT01122771

Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh

Last checked: Nov 20, 2026Latest source record: Jan 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 602 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

602

Actual

Start

May 2010

Primary completion

Mar 2014

Study completion Mar 2014

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shaheed Suhrawardy Medical College and Hospital; International Centre for Diarrhoeal Disease Research, Bangladesh
First posted
May 13, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.

Conditions

  • Visceral Leishmaniasis

Interventions

  • Liposomal amphotericin BDrug

    Ambisome i.v. 5mg on days 1, 3 and 5

  • liposomal amphotericin B + miltefosineDrug

    Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)

  • liposomal amphotericin B + paromomycinDrug

    Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).

  • Miltefosine + ParomomycinDrug

    Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Definitive cureTime frame: 6 month post treatment

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Bhaluka UZHC

    Bhaluka, Mymensingh, Bangladesh

  • Gaffargaon

    Gafargaon, Mymensingh, Bangladesh

  • Community Based Medical College

    Trishal, Mymensingh, Bangladesh

  • Trishal UZHC

    Trishal, Mymensingh, Bangladesh

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.